Literature DB >> 8740002

The Rh antigen D: partial D antigens and associated low incidence antigens.

P Tippett1, C Lomas-Francis, M Wallace.   

Abstract

The expression of the Rh antigen D varies quantitatively and qualitatively (partial D); published information and 15 years' work studying D variants are discussed in this review. D epitopes correspond to the reaction patterns of monoclonal anti-D with partial D antigens. Partial D antigens can be reported in terms of their D epitopes but the epitope profile of cells with a quantitative variant of D (weak D) is difficult to determine reliably by haemagglutination tests. Nine partial D antigens, categories II-VII, DFR and two not previously reported, are identified by their epitope profiles and by association with low incidence antigens. Monoclonal anti-D recognize 16 D epitopes and more epitopes are anticipated. The specificities of polyclonal anti-D made by people with partial D antigens are considered in terms of possible D epitope specificities: recognized epitope specificities, or combination thereof, were not able to account for all observed reaction patterns of anti-D made by immunized individuals with partial D phenotypes. An attempt is made to understand partial D antigens and their associated low incidence antigens in terms of the molecular genetic information available.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8740002     DOI: 10.1111/j.1423-0410.1996.tb01309.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  11 in total

1.  Weak D in the Tunisian population.

Authors:  Mouna Ouchari; Houda Romdhane; Taher Chakroun; Saida Abdelkefi; Batoul Houissa; Slama Hmida; Saloua Jemni Yacoub
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  STUDY OF WEAK D PHENOTYPE IN HETEROGENEOUS POPULATION.

Authors:  P S Dhot; Y V Machave
Journal:  Med J Armed Forces India       Date:  2017-06-26

3.  RHCE*ceTI encodes partial c and partial e and is often in cis to RHD*DIVa.

Authors:  Connie M Westhoff; Sunitha Vege; Christine Halter Hipsky; Kim Hue-Roye; Tamara Copeland; Randall W Velliquette; Trina Horn; Christine Lomas-Francis; Marion E Reid
Journal:  Transfusion       Date:  2012-07-13       Impact factor: 3.157

4.  Characterization of the recombination hot spot involved in the genomic rearrangement leading to the hybrid D-CE-D gene in the D(VI) phenotype.

Authors:  G Matassi; B Chérif-Zahar; I Mouro; J P Cartron
Journal:  Am J Hum Genet       Date:  1997-04       Impact factor: 11.025

5.  RHCE*ceCF encodes partial c and partial e but not CELO, an antigen antithetical to Crawford.

Authors:  Christine Halter Hipsky; Christine Lomas-Francis; Akiko Fuchisawa; Marion E Reid; Marilyn Moulds; Joann Christensen; Pam Nickle; Sunitha Vege; Connie Westhoff
Journal:  Transfusion       Date:  2011-01       Impact factor: 3.157

6.  DIIIa and DIII Type 5 are encoded by the same allele and are associated with altered RHCE*ce alleles: clinical implications.

Authors:  Connie M Westhoff; Sunitha Vege; Christine Halter-Hipsky; Trina Whorley; Kim Hue-Roye; Christine Lomas-Francis; Marion E Reid
Journal:  Transfusion       Date:  2010-01-15       Impact factor: 3.157

7.  Analysis of RHD genes in Taiwanese RhD-negative donors by the multiplex PCR method.

Authors:  Y-L Lee; H-L Chiou; S-N Hu; L Wang
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

8.  Whole exon 5 and intron 5 replaced by RHCE in DVa(Hus).

Authors:  Chaopeng Shao; Wen Xiong; Wei Wang
Journal:  J Hum Genet       Date:  2004-01-09       Impact factor: 3.172

9.  D category IV: a group of clinically relevant and phylogenetically diverse partial D.

Authors:  Inge von Zabern; Franz F Wagner; Joann M Moulds; John J Moulds; Willy A Flegel
Journal:  Transfusion       Date:  2013-03-05       Impact factor: 3.157

10.  Testing for Partial RhD with a D-Screen Diagast Kit in Moroccan Blood Donors with Weak D Expression.

Authors:  Z Kabiri; M Benajiba; K Hajjout; N Dakka; H Bellaoui
Journal:  J Blood Transfus       Date:  2014-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.